Before you sell to, join or invest in Imbria Pharmaceuticals, Inc.
MentionFox check on Imbria Pharmaceuticals, Inc.: only 2 sources on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/imbria-pharmaceuticals-inc-form-d-25000001
Check Imbria Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Imbria Pharmaceuticals, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
Imbria Pharmaceuticals, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-04-01.
Imbria Pharmaceuticals, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on April 1, 2025. The filing reports $66.70M sold. Its industry group is Biotechnology. It names Alvin Shih (Executive Officer, Director), Andrew Levin (Director), Luse Rebecca (Director) (SEC Form D/A, April 1, 2025).
Is this your company?
Sell to companies like Imbria Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-04-01 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Imbria Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Imbria Pharmaceuticals, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in April 2025, largest first.
Get an email when Imbria Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Imbria Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Imbria Pharmaceuticals, Inc. →Get the full cited report on Imbria Pharmaceuticals, Inc.
What the filing shows about Imbria Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Imbria Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Imbria Pharmaceuticals, Inc.'s address as 265 Franklin Street, Suite #1702, Boston, MA 02110.
Saved here on this device in the meantime, so nothing is lost either way.
Amended on 2025-12-16: the offering size changed from $124,195,815 to $144,195,814; the amount sold changed from $59,195,818 to $66,695,817; the number of investors changed from 8 to 10. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Imbria Pharmaceuticals, Inc. See pricing
Imbria Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1745672) and has filed since 2025-04-01. 2 filings are on record, the latest on 2025-12-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Imbria Pharmaceuticals, Inc.'s Form D of 2025-04-01 names Alvin Shih, Andrew Levin, Luse Rebecca and 5 more as its officers, directors or promoters.
Its new offerings report $59.20M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Alvin Shih is named as Executive Officer and Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Andrew Levin is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Luse Rebecca is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Charles Dunn is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Komal Joshi is named as Executive Officer on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Pavan Cheruvu is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Ken Horne is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
Zina Affas Besse is named as Director on the Form D that Imbria Pharmaceuticals, Inc. filed with the SEC on 1 April 2025, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2025-04-01 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Imbria Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Imbria Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Imbria Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Imbria Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Imbria Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Imbria Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/imbria-pharmaceuticals-inc-form-d-25000001